BibTex RIS Cite

Oral Mukozitin Önlenmesi ve Tedavisi: Güncel Yaklaşımlar

Year 2006, Volume: 4 Issue: 2, 52 - 55, 01.06.2006

Çiğdem Elbek Çubukçu Birol Baytan Adalet Meral Güneş

Abstract

Oral mukozit, kanser tedavisinde veya kök hücre ve kemik iliği nakli yapılan hastalarda, sıklıkla karşılaşılan bir sorundur. Doğası, süresi ve şiddeti tam olarak belirlenemeyen bir fonksiyon bozukluğu olup uygulanan tedaviye ve hastaya göre değikenlik gösterir 1-3 .

References

  • 1. Eilers J. Nursing interventions and supportive care for the prevention and treatment of oral mucositis associated with cancer treatment. Oncol Nurs Forum 2004; 31:13-23.
  • 2. Duncan M, Grant G. Review article: oral and intestinal mucositiscauses and possible treatments. Aliment Pharmacol Ther 2003; 18:853-74.
  • 3. Scully C, Epstein J, Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 2: Diagnosis and management of mucositis. Head&Neck 2004; 1:77-84.
  • 4. ‹lgenli T, Ören H, Uysal K. The acute effects of chemotherapy upon the oral cavity: prevention and management. Turkish J Cancer 2001; 31:93- 105.
  • 5. Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines fort he prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004; 9:2026-46.
  • 6. Brown CG, Yoder L. Stomatitis: an overview protecting the oral cavity during cancer treatment. Oncol Nurs Update 2002; 4:20-3.
  • 7. Donnelly JP, Bellm LA, Epstein JB, Sonis ST, Symonds RP. Antimicrobial therapy to prevent or treat oral mucositis. The Lancet 2003; 3:405-12.
  • 8. Barker GJ. Current practices in the oral management of the patient undergoing chemotherapy or bone marrow transplantation. Support Care Cancer 1999;7:17-20.
  • 9. Öhrn KEO, Sjödén PO. Experiences of oral care in patients with haematological malignancies or head and neck cancer. Eur J Cancer Care 2003; 12:274-82.
  • 10. Chen CF, Wang RH, Cheng SN, Chang YC. Assessment of chemotherapy-induced oral complications in children with cancer. J Ped Oncol Nurs 2004; 21:33-9.
  • 11. Miller M, Kearney N. Oral care efor patients with cancer: a review of the literature. Cancer Nurs 2001; 24:241-54.
  • 12. Kostler WJ, Hejna M, Wenzel C, Zielinski CC. Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment. CA: A cancer journal for clinicians 2001; 51:290-315.
  • 13. Shih A, Miaskowski C, Dodd MJ, Stotts NA, MacPhail L. A research review of the current treatments for radiation-induced oral mucositis in patients with head and neck cancer. Oncol Nurs Forum 2002; 29:1063-80.
  • 14. Buntzel J, Glatzel M, Kuttner K, Weinaug R, Frochlich D. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Semin Radiat Oncol 2002:12 (1, Suppl.1):4-13.
  • 15. Smith T. Gelclair: Managing the symptoms of oral mucositis. Hospit Med. 2001;62:623-6.
  • 16. Dodd MJ, Larson PJ, Dibble SL, et al. Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol Nurs Forum 1996; 23:921-7.
  • 17. Adamietz IA, Rahn R, Bottcher HD, Schafer V, Reimer K, Fleischer W. Prophylaxis with povidone-iodine against induction of oral mucositis by radiochemotherapy. Support Care Cancer 1998; 6:373-7.
  • 18. Cherchietti LC, Navigante AH, Bonomi MR, et al. Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma. Cancer 2002; 95:2230-6.
  • 19. Berger A, Henderson M, Nadoolman W, et al. Oral capsaicin provides temporary relief for oral mucoisits pain secondary to chemotherapy/radiation therapy. J Pain Symp Manag 1995; 10:243-8.
  • 20. Barasch A, Peterson DE, Tanzer JM, et al. Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer 1995; 76:2550-6.
  • 21. Cowen D, Tardieu C, Schubert MM, et al. Low energy helium-neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial. Int J Radiat Oncol Biol Phys 1997; 38:697-703.
  • 22. Knox JJ, Puodziunas ALV, Feld R. Chemotherapy-induced oral mucositis. Prevention and management. Drugs and Aging 2000; 17:257-67.
  • 23. Mantovani G, Massa E, Astara G, et al. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapyand concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs. Oncol Reports 2003; 10:197-206.
  • 24. Foncuberta MC, Cagnoni PJ, Brandts CH, et al. Topical transforming growth factor-ß 3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patints with lymphomas or solid tumors. J Immun 2001; 24:384-8.
  • 25. Subongkot S, Frame D, Leslie W, Drajer D. Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment. Pharmacotherapy 2003; 23:9-28.
  • 26. Meropol NJ, Somer RA, Gutheil J, et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 2003; 21:1452-8.
  • 27. Dorr W, Spekl K, Farell CL. Amelioration of acute oral mucositis by keratinocyte growth factor: fractioned irradation. Int J Radiat Oncol Biol Phys 2002; 54:245-51.
  • 28. Spielberger R, Emmanoulides C, Stiff P, et al. Use of recombinant human keratinocyte factor (r HuKGF) can reduce severe oral mucositis in patients with hematologic malignincies undergoing autologous peripheral blood progenitor cell transplantation (autoPBPCT) after radiation-based conditioning-results of phase 3 trial. Paper presented at the annual meeting of the American Society of Chemical Oncology, Chicago IL. June 2003.
  • 29. Okuno SH, Woodhouse CO, Loprinzi CL, et al. Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. Am J Clin Oncol 1999; 22:258-61.
  • 30. Peterson DE, Petit RG. Phase III study: AES-14 in chemotherapy patients at risk for mucositis. Paper presented at the annual meeting of the American Society of Chemical Oncology, Chicago IL. June 2003.
  • 31. Epstein JB, Silverman S Jr., Paggiarino DA, et al. Benzydamine HCL for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, doble-blind, placebo-controlled clinical trial. Cancer 2001; 92:875-85.
  • 32. Perch SJ, Machtay M, Markiewicz DA, Kligerman MM. Decreased acute toxicitiy by using midline mucosa-sparing blocks during radiaiton therapy for carcinoma of the oral cavity, oropharynx and nasopharynx. Radiol 1995; 197:863-6.
  • 33. Ship JA, Eisbruch A, D'Hondt E, Jones RE. Parotid sparing study in head and neck cancer patients receiving bilateral radiation therapy: one-year results. J Dent Res 1997; 76:807-13.

Year 2006, Volume: 4 Issue: 2, 52 - 55, 01.06.2006

Çiğdem Elbek Çubukçu Birol Baytan Adalet Meral Güneş

Abstract

References

  • 1. Eilers J. Nursing interventions and supportive care for the prevention and treatment of oral mucositis associated with cancer treatment. Oncol Nurs Forum 2004; 31:13-23.
  • 2. Duncan M, Grant G. Review article: oral and intestinal mucositiscauses and possible treatments. Aliment Pharmacol Ther 2003; 18:853-74.
  • 3. Scully C, Epstein J, Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 2: Diagnosis and management of mucositis. Head&Neck 2004; 1:77-84.
  • 4. ‹lgenli T, Ören H, Uysal K. The acute effects of chemotherapy upon the oral cavity: prevention and management. Turkish J Cancer 2001; 31:93- 105.
  • 5. Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines fort he prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004; 9:2026-46.
  • 6. Brown CG, Yoder L. Stomatitis: an overview protecting the oral cavity during cancer treatment. Oncol Nurs Update 2002; 4:20-3.
  • 7. Donnelly JP, Bellm LA, Epstein JB, Sonis ST, Symonds RP. Antimicrobial therapy to prevent or treat oral mucositis. The Lancet 2003; 3:405-12.
  • 8. Barker GJ. Current practices in the oral management of the patient undergoing chemotherapy or bone marrow transplantation. Support Care Cancer 1999;7:17-20.
  • 9. Öhrn KEO, Sjödén PO. Experiences of oral care in patients with haematological malignancies or head and neck cancer. Eur J Cancer Care 2003; 12:274-82.
  • 10. Chen CF, Wang RH, Cheng SN, Chang YC. Assessment of chemotherapy-induced oral complications in children with cancer. J Ped Oncol Nurs 2004; 21:33-9.
  • 11. Miller M, Kearney N. Oral care efor patients with cancer: a review of the literature. Cancer Nurs 2001; 24:241-54.
  • 12. Kostler WJ, Hejna M, Wenzel C, Zielinski CC. Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment. CA: A cancer journal for clinicians 2001; 51:290-315.
  • 13. Shih A, Miaskowski C, Dodd MJ, Stotts NA, MacPhail L. A research review of the current treatments for radiation-induced oral mucositis in patients with head and neck cancer. Oncol Nurs Forum 2002; 29:1063-80.
  • 14. Buntzel J, Glatzel M, Kuttner K, Weinaug R, Frochlich D. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Semin Radiat Oncol 2002:12 (1, Suppl.1):4-13.
  • 15. Smith T. Gelclair: Managing the symptoms of oral mucositis. Hospit Med. 2001;62:623-6.
  • 16. Dodd MJ, Larson PJ, Dibble SL, et al. Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol Nurs Forum 1996; 23:921-7.
  • 17. Adamietz IA, Rahn R, Bottcher HD, Schafer V, Reimer K, Fleischer W. Prophylaxis with povidone-iodine against induction of oral mucositis by radiochemotherapy. Support Care Cancer 1998; 6:373-7.
  • 18. Cherchietti LC, Navigante AH, Bonomi MR, et al. Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma. Cancer 2002; 95:2230-6.
  • 19. Berger A, Henderson M, Nadoolman W, et al. Oral capsaicin provides temporary relief for oral mucoisits pain secondary to chemotherapy/radiation therapy. J Pain Symp Manag 1995; 10:243-8.
  • 20. Barasch A, Peterson DE, Tanzer JM, et al. Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer 1995; 76:2550-6.
  • 21. Cowen D, Tardieu C, Schubert MM, et al. Low energy helium-neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial. Int J Radiat Oncol Biol Phys 1997; 38:697-703.
  • 22. Knox JJ, Puodziunas ALV, Feld R. Chemotherapy-induced oral mucositis. Prevention and management. Drugs and Aging 2000; 17:257-67.
  • 23. Mantovani G, Massa E, Astara G, et al. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapyand concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs. Oncol Reports 2003; 10:197-206.
  • 24. Foncuberta MC, Cagnoni PJ, Brandts CH, et al. Topical transforming growth factor-ß 3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patints with lymphomas or solid tumors. J Immun 2001; 24:384-8.
  • 25. Subongkot S, Frame D, Leslie W, Drajer D. Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment. Pharmacotherapy 2003; 23:9-28.
  • 26. Meropol NJ, Somer RA, Gutheil J, et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 2003; 21:1452-8.
  • 27. Dorr W, Spekl K, Farell CL. Amelioration of acute oral mucositis by keratinocyte growth factor: fractioned irradation. Int J Radiat Oncol Biol Phys 2002; 54:245-51.
  • 28. Spielberger R, Emmanoulides C, Stiff P, et al. Use of recombinant human keratinocyte factor (r HuKGF) can reduce severe oral mucositis in patients with hematologic malignincies undergoing autologous peripheral blood progenitor cell transplantation (autoPBPCT) after radiation-based conditioning-results of phase 3 trial. Paper presented at the annual meeting of the American Society of Chemical Oncology, Chicago IL. June 2003.
  • 29. Okuno SH, Woodhouse CO, Loprinzi CL, et al. Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. Am J Clin Oncol 1999; 22:258-61.
  • 30. Peterson DE, Petit RG. Phase III study: AES-14 in chemotherapy patients at risk for mucositis. Paper presented at the annual meeting of the American Society of Chemical Oncology, Chicago IL. June 2003.
  • 31. Epstein JB, Silverman S Jr., Paggiarino DA, et al. Benzydamine HCL for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, doble-blind, placebo-controlled clinical trial. Cancer 2001; 92:875-85.
  • 32. Perch SJ, Machtay M, Markiewicz DA, Kligerman MM. Decreased acute toxicitiy by using midline mucosa-sparing blocks during radiaiton therapy for carcinoma of the oral cavity, oropharynx and nasopharynx. Radiol 1995; 197:863-6.
  • 33. Ship JA, Eisbruch A, D'Hondt E, Jones RE. Parotid sparing study in head and neck cancer patients receiving bilateral radiation therapy: one-year results. J Dent Res 1997; 76:807-13.
There are 33 citations in total.

Details

Primary Language Turkish
Journal Section Collection
Authors

Çiğdem Elbek Çubukçu This is me

Birol Baytan This is me

Adalet Meral Güneş This is me

Publication Date June 1, 2006
Published in Issue Year 2006 Volume: 4 Issue: 2

Cite

APA Çubukçu, Ç. E., Baytan, B., & Güneş, A. M. (2006). Oral Mukozitin Önlenmesi ve Tedavisi: Güncel Yaklaşımlar. Güncel Pediatri, 4(2), 52-55.
AMA Çubukçu ÇE, Baytan B, Güneş AM. Oral Mukozitin Önlenmesi ve Tedavisi: Güncel Yaklaşımlar. Güncel Pediatri. June 2006;4(2):52-55.
Chicago Çubukçu, Çiğdem Elbek, Birol Baytan, and Adalet Meral Güneş. “Oral Mukozitin Önlenmesi Ve Tedavisi: Güncel Yaklaşımlar”. Güncel Pediatri 4, no. 2 (June 2006): 52-55.
EndNote Çubukçu ÇE, Baytan B, Güneş AM (June 1, 2006) Oral Mukozitin Önlenmesi ve Tedavisi: Güncel Yaklaşımlar. Güncel Pediatri 4 2 52–55.
IEEE Ç. E. Çubukçu, B. Baytan, and A. M. Güneş, “Oral Mukozitin Önlenmesi ve Tedavisi: Güncel Yaklaşımlar”, Güncel Pediatri, vol. 4, no. 2, pp. 52–55, 2006.
ISNAD Çubukçu, Çiğdem Elbek et al. “Oral Mukozitin Önlenmesi Ve Tedavisi: Güncel Yaklaşımlar”. Güncel Pediatri 4/2 (June 2006), 52-55.
JAMA Çubukçu ÇE, Baytan B, Güneş AM. Oral Mukozitin Önlenmesi ve Tedavisi: Güncel Yaklaşımlar. Güncel Pediatri. 2006;4:52–55.
MLA Çubukçu, Çiğdem Elbek et al. “Oral Mukozitin Önlenmesi Ve Tedavisi: Güncel Yaklaşımlar”. Güncel Pediatri, vol. 4, no. 2, 2006, pp. 52-55.
Vancouver Çubukçu ÇE, Baytan B, Güneş AM. Oral Mukozitin Önlenmesi ve Tedavisi: Güncel Yaklaşımlar. Güncel Pediatri. 2006;4(2):52-5.